Initiator Pharma A/S is a clinical-stage biotechnology company, which engages in the development of novel therapeutics within the field of mono-amine reuptake transporters targeting central nervous system (CNS)-disorders. Its portfolio consists of IPED2015, represents a novel treatment paradigm for the treatment of organic erectile dysfunction (ED); and IP2018, a drug candidate for the treatment of psychogenic ED and depression. The company was founded by Claus Elsborg Olesen, Dan Peters, Ulf Simonsen, and Mikael Sondergaard Thomsen in 2016 and is headquartered in Copenhagen, Denmark.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company